Skip to Content

AI-POWERED FEASIBILITY GROUNDED IN THERAPEUTIC EXPERTISE.

Biorasi combines dynamic site modeling, feasibility outreach, and real-time enrollment forecasting to give sponsors a data-verified foundation for trial success.

REQUEST A PROPOSAL

WHY BIORASI FOR FEASIBILITY?

Feasibility is more than a site checklist — it is crucial to successful strategies. Feasibility solutions at Biorasi integrate operational discipline, patient access insights, KOL-driven medical expertise, and now, real-time AI data. The result: smarter site selection, reduced startup delays, and reliable enrollment forecasts.

 

 

The Rescue Advantage

ReliabilityReliability

AI and evidence-based feasibility that anticipates and mitigates risks.

Flexibility

Flexibility

Tailored assessments that match important goals – from global enrollment to clinical site expansion.

Accessibility

Accessibility

Full transparency through our Beeline visual data dashboards as well as direct sponsor-team access.

 

Key Data Capabilities

KEY CAPABILITIES

+
  • Dynamic AI digital twins of global research sites, continuously updated with patient pools and site readiness.
  • Automated feasibility forms that pre-fill with validated data, cutting feasibility cycles to under 3 weeks.
  • Agentic copilots for protocol parsing and automated document generation.

Therapeutic Impact

+

Dermatology

  • Improves enrollment velocity forecasting.

Oncology

  • Instant access to high-performance cancer centers.

Neurology

  • Reduces screen failure risk in rare disease studies.

Nephrology

  • Predicts eligible patient pools with higher accuracy.

Benefits to Sponsors

+
  • More accurate enrollment forecasts and budget modeling.
  • Faster site startup through automation and site prequalification.
  • Reduced mid-trial delays and cost overruns.
  • Improved site engagement with high-fit, high-capacity partners.

 

AI-Driven Feasibility

Biorasi has announced a strategic partnership with Ryght AI to bring advanced, AI-driven feasibility capabilities to sponsors.

 

FROM OUR PARTNERS